Defeat Duchenne Canada Launches New Clinical Trial Finder Tool

Defeat Duchenne Canada is proud to announce the launch of the first Clinical Trial Finder Tool for Duchenne and Becker muscular dystrophy in Canada.

Visit the Clinical Trial Finder Tool

Duchenne and Becker muscular dystrophy are progressive neuromuscular disorders with no cure. Affecting approximately 1 in every 5,000 boys in Canada, both Becker and Duchenne are caused by mutations within the dystrophin gene, one of the largest genes in the body responsible for strengthening muscles and protecting them from injury.

When the organization first began its quest for a cure twenty-six years ago, there was very little research and no clinical trials. Since then, numerous organizations, like Defeat Duchenne Canada, have transformed the landscape by investing in the most promising science focused on prevention, improved treatments, and a better quality of life for individuals living with Duchenne and Becker.

“We have developed an innovative Clinical Trial Finder Tool for those living with Duchenne and Becker muscular dystrophy. The tool helps gather comprehensive information on existing and pending clinical trials in Canada and beyond, allowing our community to easily personalize and navigate the latest information to help make informed choices about their participation,” shares Nicola Worsfold, Vice-President of Research, Advocacy and Education at Defeat Duchenne Canada.

“Being involved in a clinical trial is not a decision that can be made lightly,” she continues. “While it offers the possibility of hope, it also involves many sacrifices from the whole family. We want to empower our community with accurate, up-to-date information to facilitate informed decision making with their health care team.”

Watch the Defeat Duchenne Canada webinar launch of their Clinical Trial Finder Tool


Defeat Duchenne Canada has built a foundation of strong partnerships with leading scientists and industry partners to improve care for individuals living with Duchenne and Becker. When they heard the need from their community for more resources regarding clinical trials, the organization turned to Lumiio, a global digital health company specializing in real-world data collection services that drive health outcomes.
“We were thrilled to be able to work with Defeat Duchenne Canada in the development of a tool that helps close knowledge gaps around clinical trial opportunities,” said Josh Lounsberry, Chief Strategy Officer at Lumiio, “The needs of the Duchenne community align perfectly with Lumiio’s mission of accelerating health outcomes through data.”

Learn more about the Clinical Trial Finder Tool


Read the full press release from Defeat Duchenne Canada

Defeat Duchenne Canada's Clinical Trial Finder Tool

Read next...

Meet the Fellows - now live

Meet the Fellows Video Series

The NMD4C and MDC are excited to share a new videos series featuring five incredible fellows Drs. Emanuela Pannia, Rebecca Robertson, Collin Luk, Marianne Nury and Alasdair Rathbone.

Application for AFC in neuromuscular medicine approved by the Royal College

Area of Focused Competency in Neuromuscular Medicine Approved by Royal College of Physicians and Surgeons of Canada

The Neuromuscular Disease Network for Canada (NMD4C) are pleased to announce that on May 3rd, 2022, the Royal College of Physicians and Surgeons of Canada approved an application for neuromuscular medicine to be recognized as an area of focused competency (AFC) discipline. This recognition is a significant step in raising the standards of care for people affected by neuromuscular diseases in Canada.

KT infographic logo

Knowledge Translation Team Share Clinical Practice Guideline Infographic

The Knowledge Translation team are are glad to share an infographic of the clinical practice guideline “Promoting Sexuality and Intimate Relationships in Adults with a NMD in Occupational Therapy”

Upcoming neuromuscular conferences

Upcoming Neuromuscular Conferences in 2022

This year we are excited to anticipate the return of in-person conferences, which provide an invaluable training and networking experience to all members of the neuromuscular community and which have been dearly missed over the past two years. In 2022, Canada will host several major neuromuscular conferences, both domestic and international. Please take a moment…

Knowledge Translation Canada logo

Network’s Approach to Adapting Knowledge Translation Strategies for Neuromuscular Diseases: Knowledge Translation Canada Scientific Meeting

on behalf of the NMD4C Knowledge Translation team, Drs. Cynthia Gagnon and Homira Osman have had a poster presentation accepted for inclusion at the Knowledge Translation Canada (KT Canada) 2022 Virtual Scientific Meeting.

Dr. Emanuela Pannia EC Blog

Read NMD4C and MDC Postdoc Fellowship Recipient Dr. Emanuela Pannia’s Early-Career Blog

Read the latest early career blog post, from NMD4C and MDC Postdoc Fellowship Recipient Dr. Emanuela Pannia.